Ensysce Biosciences, Inc. (ENSC) — Financial statements
Income statement, balance sheet, and cash flow for Ensysce Biosciences, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 5↓2.8% | 5↑133.5% | 2↓11.6% | 3↓28.5% | 4 | |
| Cost of Revenue | 0.00↓100.0% | 7↓4.9% | 8↓61.8% | 20↑13136241.1% | 0.00 | |
| Gross Profit | 0.00↑100.0% | -2↑62.5% | -5↑69.1% | -17↓590.3% | 4 | |
| Operating Expenses | ||||||
| R&D Expenses | 10,376,895↑143744116.7% | 7↓4.9% | 8↓61.8% | 20↑322.9% | 5 | |
| General & Administrative Expenses | 4,930,701↑104441776.7% | 5↓11.9% | 5↓22.4% | 7 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 4,930,701↑104441776.7% | 5↓11.9% | 5↓22.4% | 7↓63.1% | 19 | |
| Other Expenses | -15,307,586↓212045692.5% | -7↑4.9% | -8↑61.8% | -20 | 0.00 | |
| Operating Expenses | 10↑116.9% | 5↓11.9% | 5↓22.4% | 7↓70.5% | 23 | |
| Total Costs & Expenses | 10↓14.2% | 12↓7.8% | 13↓51.6% | 27↑14.3% | 23 | |
| Operating Results | ||||||
| Operating Income | -10↓52.2% | -7↑37.2% | -11↑55.8% | -24↓21.9% | -20 | |
| Depreciation & Amortization | 0.01↑163225.0% | 0.00↑233.3% | -0.00↓102.0% | 0.00↑0.0% | 0.00 | |
| EBITDA | -10↓50.8% | -7↑37.2% | -11↑55.8% | -24↑6.6% | -26 | |
| EBIT | -10↓50.9% | -7↑37.2% | -11↑55.8% | -24↑6.6% | -26 | |
| Interest & Other Income | ||||||
| Net Interest Income | -0.02↑98.5% | -1↓264.4% | -0.35↓131.1% | 1↓40.7% | 2 | |
| Interest Income | 0.00 | 0.00 | 0.00↓100.0% | 1↓61.2% | 3 | |
| Interest Expense | 0.02↓98.5% | 1↑264.5% | 0.35↑223.2% | 0.11↓91.5% | 1 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 6 | |
| Other Income / Expenses | 0.06↑105.2% | -1↓1467.6% | 0.09↑537.8% | 0.01↑100.2% | -9 | |
| Income Before Tax | -10↓27.4% | -8↑24.8% | -11↑56.1% | -24↑16.9% | -29 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -10↓27.4% | -8↑24.8% | -11↑56.1% | -24↑16.9% | -29 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -10↓27.4% | -8↑24.7% | -11↑56.1% | -24↑16.9% | -29 | |
| Bottom-Line Net Income | -10↓27.4% | -8↑24.8% | -11↑57.6% | -25↑16.1% | -30 | |
| EPS (Basic) | -3.98↑12.9% | -4.57↑2.6% | -4.69↑96.6% | -139.44↑60.8% | -355.68 | |
| EPS (Diluted) | -3.98↑12.9% | -4.57↑2.6% | -4.69↑96.6% | -139.44↑60.8% | -355.68 | |
| Weighted Average Shares | 3↑46.4% | 2↓22.8% | 2↑1158.3% | 0.18↑114.2% | 0.08 | |
| Weighted Average Diluted Shares | 26↑1363.9% | 2↓22.8% | 2↑1158.3% | 0.18↑114.2% | 0.08 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.